GILD · Gilead Sciences, Inc. · Insider Trading

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $137.75 to $138.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $129.45 to $130.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.